WO2005094771A1 - Topische zubereitung zur anwendung auf der haut enthaltend natürliches öl der nachtkerze (oenothera biennis) (=oleum oenotherae) und osmolyte aus extremophilen mikroorganismen - Google Patents
Topische zubereitung zur anwendung auf der haut enthaltend natürliches öl der nachtkerze (oenothera biennis) (=oleum oenotherae) und osmolyte aus extremophilen mikroorganismen Download PDFInfo
- Publication number
- WO2005094771A1 WO2005094771A1 PCT/EP2005/003342 EP2005003342W WO2005094771A1 WO 2005094771 A1 WO2005094771 A1 WO 2005094771A1 EP 2005003342 W EP2005003342 W EP 2005003342W WO 2005094771 A1 WO2005094771 A1 WO 2005094771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osmolyte
- oil
- evening primrose
- formulation
- skin
- Prior art date
Links
- 230000000065 osmolyte Effects 0.000 title claims abstract description 47
- 244000005700 microbiome Species 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 15
- 235000004496 Oenothera biennis Nutrition 0.000 title claims description 11
- 230000000699 topical effect Effects 0.000 title claims description 7
- 235000008524 evening primrose extract Nutrition 0.000 title abstract description 48
- 239000010475 evening primrose oil Substances 0.000 title abstract description 43
- 229940089020 evening primrose oil Drugs 0.000 title abstract description 43
- 240000008916 Oenothera biennis Species 0.000 title description 5
- 229940045761 evening primrose extract Drugs 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 238000009472 formulation Methods 0.000 claims abstract description 25
- 239000003921 oil Substances 0.000 claims abstract description 19
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims description 18
- 210000003491 skin Anatomy 0.000 claims description 14
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 claims description 7
- 241000219925 Oenothera Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- DDXCFDOPXBPUJC-MTXRGOKVSA-N 2-(beta-D-mannosyl)-D-glyceric acid Chemical compound OC[C@H](C(O)=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O DDXCFDOPXBPUJC-MTXRGOKVSA-N 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 235000014593 oils and fats Nutrition 0.000 claims description 5
- 230000006641 stabilisation Effects 0.000 claims description 5
- 238000011105 stabilization Methods 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims 3
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- PZJOIILIPTVGFU-UWTATZPHSA-N cyclic 2,3-bisphospho-D-glyceric acid Chemical compound OC(=O)[C@H]1COP(O)(=O)OP(O)(=O)O1 PZJOIILIPTVGFU-UWTATZPHSA-N 0.000 claims 2
- 239000011505 plaster Substances 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- 239000004904 UV filter Substances 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000007934 lip balm Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 244000005706 microflora Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000008591 skin barrier function Effects 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000003925 fat Substances 0.000 abstract description 4
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 5
- 150000002319 glycerophosphoglycerols Chemical class 0.000 description 5
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XOHUEYCVLUUEJJ-UWTATZPHSA-N 2,3-bisphospho-D-glyceric acid Chemical compound OP(=O)(O)O[C@@H](C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UWTATZPHSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229960002733 gamolenic acid Drugs 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- -1 vitamin E Natural products 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- DDXCFDOPXBPUJC-UHFFFAOYSA-N Digeneaside Natural products OCC(C(O)=O)OC1OC(CO)C(O)C(O)C1O DDXCFDOPXBPUJC-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002432 hydroperoxides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 235000003277 Cereus hexagonus Nutrition 0.000 description 1
- 235000001259 Cereus jamacaru Nutrition 0.000 description 1
- 235000009241 Cereus peruvianus Nutrition 0.000 description 1
- 235000012001 Cestrum nocturnum Nutrition 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000018481 Hylocereus undatus Nutrition 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000090896 Nigella sativa Species 0.000 description 1
- 235000016698 Nigella sativa Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000219929 Onagraceae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940058307 antinematodal tetrahydropyrimidine derivative Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- Topical preparation for use on the skin containing natural evening primrose oil (Oenothera biennis) ( Oleum Oenotherae) and osmolytes from extremophilic microorganisms
- the invention relates to a formulation which contains an osmolyte from extremophilic microorganisms and unsaturated fatty acids containing natural oils and fats.
- the formulation contains at least one osmolyte in an amount of 0.01 to 50 wt .-%, based on the total weight of the formulation.
- the invention relates to the use of an osmolyte formed by extremophilic bacteria (e.g. ectoin, hydroxyectoin, Firoin, Firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, di-inositol phosphate; hereinafter referred to as Osmolyte X) in combination with natural evening primrose oil (Oleum Oenotherae) for the production of drugs, medical devices or cosmetics for external treatment, prophylaxis or care of the skin.
- extremophilic bacteria e.g. ectoin, hydroxyectoin, Firoin, Firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, di-inositol phosphate; hereinafter referred to as Osmolyte X
- Osmolyte X natural evening primrose oil
- Certain fatty acids are essential for the human organism, i.e. they must be ingested with the food if there are no symptoms of deficiency.
- These include polyunsaturated fatty acids (PUFAs) from the Omega 6 and Omega 3 series, such as linoleic acid and alpha-linolenic acid, which, as precursors to eicosanoids, influence a wide range of physiological functions.
- PUFAs polyunsaturated fatty acids
- the stability of the fats is also heavily dependent on the percentage of PUFAs.
- the influence of oxygen, light and heat can lead to the formation of
- PUFA polyunsaturated fatty acids
- Naturally occurring unsaturated fatty acids usually have the cis configuration on the double bonds. So-called.
- Trans fats result from the "hardening" of fat, whereby the double bonds of the unsaturated fatty acids are hydrogenated with hydrogen and vegetable fats are formed which are solid even at room temperature.
- Osmolytes or compatible solutes from extremophilic microorganisms form a well-known group of low-molecular protective substances. Extremophiles are very unusual microorganisms, because they optimally e.g. grow at high salt concentrations (up to 200 g NaCI / l) and high temperatures (60-110 ° C), which would lead to massive damage to cellular structures in mesophilic ("normal") organisms.
- the osmolytes (compatible solutes) found in the extremophilic microorganisms are not produced by human or animal cells.
- the osmolyt ectoin was previously used as a moisturizer and active ingredient in cosmetic products with the aim of protecting healthy, clinically unremarkable human skin against the damaging effects of ultraviolet solar radiation (e.g. Use of ectoine or ectoine derivatives in cosmetic formulations, EP19990941; Use of ectoine or ectoine derivatives for the prophylaxis and / or treatment of UV induced immunosuppression).
- the evening primrose (Oenothera biennis; Onagraceae plant family), also known as the "Queen of the Night", is a plant and bears its name because it opens its bright yellow flowers in the evening or in cloudy weather.
- the Algonkin Indians treated various skin conditions with a slurry of crushed evening primrose oil seeds (Oleum Oenotherae) over 500 years ago.
- the oil obtained from the evening primrose's flower seeds has a high proportion of polyunsaturated fatty acids such as linoleic acid and gamma-linolenic acid.
- the seeds used for oil production come from plants grown without chemical pesticides.
- Evening primrose oil is a natural and biologically active source of essential fatty acids, including cis-gammalinolenic acid (GLA) with a share of approx. 10%.
- GLA cis-gammalinolenic acid
- the acidity is active thanks to the unique triglizeryd structure, which is unique to evening primrose oil.
- Cold-extracted evening primrose oil contains important amino acids, minerals and vitamins, including vitamin E, which plays the natural role of an antioxidant.
- the oil is not only used in high-quality cosmetic products, but is also used as a valuable nutritional supplement. Numerous cosmetic products describe the care effects of evening primrose oil on very dry, irritated, flaky and problematic skin. Evening primrose oil can also be used internally as a nutritional supplement.
- evening primrose oil (Oleum Oenotherae) in topical preparations is severely limited due to its short shelf life. Since it is perishable, evening primrose oil is usually preserved with vitamin E. In addition, evening primrose oil is always mixed with another base oil to increase stability. This significantly improves the durability. Heating evening primrose oil e.g. for conservation purposes is not possible due to instability.
- fish oil e.g. mackerel, tuna, salmon, herring
- coconut oil palm oil
- Cocoa oil olive oil, peanut oil, cottonseed oil, sesame oil, corn oil, safflower oil, soybean oil, wheat oil, borage oil, linseed oil, rapeseed oil, black nettle oil, castor oil, black cumin oil, rose hip seed oil, hemp oil and the like.
- an evening primrose-oil based care product of the same composition with the addition of 0.5% (weight percent) of the osmolyte ectoin has a significantly better care effect with very dry, irritated, flaky and problematic Skin showed.
- the care effect of the combination product of evening primrose oil and osmolyte was significantly better than that of a care product that only contained the osmolyte in a 0.5% concentration.
- a topical preparation containing a combination of evening primrose oil (Oleum Oenotherae) and Osmolyte X for cosmetic and dermatological applications thus surprisingly had the significant advantage of a significantly improved preservation and longer shelf life with a synergistically increased care effect for very dry, irritated, flaky and problematic skin ,
- This means that a preparation made from osmolyte and evening primrose oil is also ideal for the care of inflamed areas of the skin, such as those e.g. in people suffering from atopic dermatitis.
- the cosmetic and dermatological formulations are produced by one or more compounds from the group of the osmolytes, the physiologically tolerable salts of the compounds of the osmolyte in
- the auxiliaries and carriers come from the group of carriers, preservatives and other customary auxiliaries.
- the osmolytes contained in cosmetic and dermatological formulations and the evening primrose oil are used externally.
- solutions, suspensions, emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleaning preparations, oils and sprays e.g., any customary carriers, auxiliaries and, if appropriate, further active compounds can be added to the formulations.
- Preferred additives come from the group of preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants and
- ointments, pastes, creams and gels can contain the usual carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.
- carriers e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.
- Powder and sprays can, in addition to one or more compounds from the group of osmolytes plus evening primrose oil, in addition to the usual carriers, the usual blowing agents, e.g. Chlorofluorocarbons, propane / butane or dimethyl ether.
- the usual blowing agents e.g. Chlorofluorocarbons, propane / butane or dimethyl ether.
- solutions and emulsions may contain the usual carriers such as solvents, solubilizers and emulsifiers.
- Suspensions can be selected in addition to one or more compounds from the group of Osmolyte X plus evening primrose oil (Oleum Oenotherae) such as. B. contain water or ethanol.
- Other application forms are e.g. B. soaps, surfactant-containing cleaning agents, facial and body oils, lipsticks, lip care sticks, mascara, eyeliner, eye shadow, blush, powder, emulsion and wax make-up as well as sunscreen, pre-sun and after-sun preparations.
- the proportion of the compounds of the Osmolyte X group in cosmetic and dermatological formulations is preferably 0.0001 to 50% by weight, particularly preferably 0.001 to 10% by weight, based on the preparation as a whole.
- the proportion of evening primrose oil (Oleum Oenotherae) in cosmetic and dermatological formulations is preferably 0.0001 to 50% by weight, particularly preferably 0.001 to 10% by weight, based on the preparation as a whole.
- a lotion (O / W) according to the invention containing Osmolyte X and evening primrose oil (Oleum Oenotherae) is produced from the following components:
- a cream (O / W) according to the invention containing Osmolyt X is produced from the following components:
- a cream (O / W) according to the invention containing osmolyte cyclic diphosphoglycerate (cDPG) is produced from the following components:
- the stability of evening primrose oil at higher temperatures strongly depends on the proportion of ⁇ -linolenic acid and the purity of the evening primrose oil.
- room temperature 25 ° C
- diglycerol phosphate 0.1% (percent by weight) of diglycerol phosphate to a preparation of evening primrose oil
- an increased storage stability of evening primrose oil of five days was found compared to the control without diglycerol phosphate.
- the stability of the preparation was assessed based on the first appearance of a rancid smell of evening primrose oil.
- a gel (O / W) according to the invention containing diinositol phosphate and evening primrose oil is produced from the following components:
- a sun protection emulsion according to the invention containing evening primrose oil and hydroxyectoin is produced from the following components:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/594,576 US20080014153A1 (en) | 2004-03-30 | 2005-03-30 | Topical Preparation For Application To The Skin Containing Natural Oil Of The Evening Primrose (Oenothera Biennis) (=Oleum Oenotherae) And Osmolytes Originating From Extremophilic Microorganisms |
JP2007505492A JP2007530624A (ja) | 2004-03-30 | 2005-03-30 | 月見草(OenotheraBiennis)の天然油(=OleumOenotherae)および極限環境微生物から生じるオスモライトを含有する、皮膚に使用するための局所製剤 |
EP05716456A EP1732651A1 (de) | 2004-03-30 | 2005-03-30 | Topische zubereitung zur anwendung auf der haut enthaltend natürliches öl der nachtkerze (oenothera biennis) (=oleum oenotherae) und osmolyte aus extremophilen mikroorganismen |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004016045.7 | 2004-03-30 | ||
DE102004016045 | 2004-03-30 | ||
DE102004049062.7 | 2004-10-08 | ||
DE102004049062A DE102004049062A1 (de) | 2004-03-30 | 2004-10-08 | Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenothera) und Osmolyte aus extremophilen Mikroorganismen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094771A1 true WO2005094771A1 (de) | 2005-10-13 |
Family
ID=34965024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/003342 WO2005094771A1 (de) | 2004-03-30 | 2005-03-30 | Topische zubereitung zur anwendung auf der haut enthaltend natürliches öl der nachtkerze (oenothera biennis) (=oleum oenotherae) und osmolyte aus extremophilen mikroorganismen |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080014153A1 (de) |
EP (1) | EP1732651A1 (de) |
JP (1) | JP2007530624A (de) |
DE (1) | DE102004049062A1 (de) |
WO (1) | WO2005094771A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008064916A2 (de) * | 2006-12-01 | 2008-06-05 | bitop Aktiengesellschaft für biotechnische Optimierung | Mittel zur behandlung von vascular leaks |
EP2214658B2 (de) † | 2007-10-31 | 2021-08-04 | Bitop AG | Osmolythaltige zubereitung zur anwendung bei trockenen schleimhäuten |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097263A2 (de) * | 2005-03-12 | 2006-09-21 | bitop Aktiengesellschaft für biotechnische Optimierung | Kompatible solute enthaltende mittel zur oralen verwendung |
DE102007013857A1 (de) * | 2007-03-20 | 2008-09-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Neue Zusammensetzungen, insbesondere für die topische Behandlung von Hauterkrankungen |
FR2916977A1 (fr) * | 2007-06-06 | 2008-12-12 | Engelhard Lyon Sa | STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE. |
DE102007040615A1 (de) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen |
DE102008039231A1 (de) * | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
EP2184052B1 (de) * | 2008-11-11 | 2017-09-20 | Kao Germany GmbH | Haarzusammensetzung |
WO2011082027A1 (en) * | 2009-12-30 | 2011-07-07 | The Procter & Gamble Company | Wipe article comprising lotion composition comprising omega - 6 fatty acid |
KR101275351B1 (ko) * | 2010-06-29 | 2013-06-17 | (주)아모레퍼시픽 | 노화방지용 화장료 조성물 |
EP2646014A2 (de) * | 2010-12-01 | 2013-10-09 | Nostrum Laboratories, Inc. | Topische formulierungen zur verabreichung von omega-3-fettsäuren |
CN102274229A (zh) * | 2011-09-01 | 2011-12-14 | 朱道辰 | 一种治疗皮炎的外用药物及其制法 |
KR101694938B1 (ko) * | 2013-04-10 | 2017-01-11 | 주식회사 유엑스엔 | 골드비드를 함유한 비누, 화장품 조성물 및 이를 이용한 비누, 화장품 제조방법 |
WO2016176485A1 (en) * | 2015-04-29 | 2016-11-03 | Petkoska Anka T | Antioxidant compositions and methods of protecting skin, hair and nails against high energy blue-violet light |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178908A (ja) * | 1984-02-27 | 1986-08-11 | Kanebo Ltd | 皮膚化粧料 |
JPS6416890A (en) * | 1987-07-10 | 1989-01-20 | Shiseido Co Ltd | Antioxidant |
EP0816509A2 (de) * | 1996-06-28 | 1998-01-07 | IBET - Instituto de Biologia Experimental e Tecnologica | Thermostabilisierung, Osmoseschütz und Trocknungsschütz von Enzymen, Zellinhaltstoffen und Zellen mit Mannosyl-Glycerat |
DE19911775A1 (de) * | 1998-08-01 | 2000-02-03 | Merck Patent Gmbh | Verwendung von Ectoin oder Ectoin-Derivaten in kosmetischen Formulierungen |
WO2001076572A2 (de) * | 2000-04-12 | 2001-10-18 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften |
DE10040931A1 (de) * | 2000-08-18 | 2002-03-07 | Bitop Gmbh | Verwendung von cyclischem 2,4 Diphosphoglycerat (cDGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen |
DE10040933A1 (de) * | 2000-08-18 | 2002-03-07 | Bitop Gmbh | Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen |
WO2005002581A1 (de) * | 2003-07-03 | 2005-01-13 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen bakterien gewonnenen osmolyten zur herstellung von arzneimitteln zur äusserlichen behandlung der neurodermitis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2557452B1 (fr) * | 1983-12-28 | 1986-08-14 | Roussel Uclaf | Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate |
DE4342560A1 (de) * | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten |
ES2228089T3 (es) * | 1998-08-01 | 2005-04-01 | Merck Patent Gmbh | Empleo de ectoina o derivados de ectoina en formulaciones cosmeticas. |
DE19834818A1 (de) * | 1998-08-01 | 2000-02-03 | Merck Patent Gmbh | Kosmetische Formulierung |
-
2004
- 2004-10-08 DE DE102004049062A patent/DE102004049062A1/de not_active Withdrawn
-
2005
- 2005-03-30 WO PCT/EP2005/003342 patent/WO2005094771A1/de active Application Filing
- 2005-03-30 EP EP05716456A patent/EP1732651A1/de not_active Withdrawn
- 2005-03-30 JP JP2007505492A patent/JP2007530624A/ja active Pending
- 2005-03-30 US US10/594,576 patent/US20080014153A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178908A (ja) * | 1984-02-27 | 1986-08-11 | Kanebo Ltd | 皮膚化粧料 |
JPS6416890A (en) * | 1987-07-10 | 1989-01-20 | Shiseido Co Ltd | Antioxidant |
EP0816509A2 (de) * | 1996-06-28 | 1998-01-07 | IBET - Instituto de Biologia Experimental e Tecnologica | Thermostabilisierung, Osmoseschütz und Trocknungsschütz von Enzymen, Zellinhaltstoffen und Zellen mit Mannosyl-Glycerat |
DE19911775A1 (de) * | 1998-08-01 | 2000-02-03 | Merck Patent Gmbh | Verwendung von Ectoin oder Ectoin-Derivaten in kosmetischen Formulierungen |
WO2001076572A2 (de) * | 2000-04-12 | 2001-10-18 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften |
DE10040931A1 (de) * | 2000-08-18 | 2002-03-07 | Bitop Gmbh | Verwendung von cyclischem 2,4 Diphosphoglycerat (cDGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen |
DE10040933A1 (de) * | 2000-08-18 | 2002-03-07 | Bitop Gmbh | Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen |
WO2005002581A1 (de) * | 2003-07-03 | 2005-01-13 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen bakterien gewonnenen osmolyten zur herstellung von arzneimitteln zur äusserlichen behandlung der neurodermitis |
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 010, no. 390 (C - 394) 26 December 1986 (1986-12-26) * |
PATENT ABSTRACTS OF JAPAN vol. 013, no. 190 (C - 593) 8 May 1989 (1989-05-08) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008064916A2 (de) * | 2006-12-01 | 2008-06-05 | bitop Aktiengesellschaft für biotechnische Optimierung | Mittel zur behandlung von vascular leaks |
WO2008064916A3 (de) * | 2006-12-01 | 2008-10-09 | Bitop Ag | Mittel zur behandlung von vascular leaks |
EP2214658B2 (de) † | 2007-10-31 | 2021-08-04 | Bitop AG | Osmolythaltige zubereitung zur anwendung bei trockenen schleimhäuten |
Also Published As
Publication number | Publication date |
---|---|
US20080014153A1 (en) | 2008-01-17 |
EP1732651A1 (de) | 2006-12-20 |
DE102004049062A1 (de) | 2005-10-13 |
JP2007530624A (ja) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005094771A1 (de) | Topische zubereitung zur anwendung auf der haut enthaltend natürliches öl der nachtkerze (oenothera biennis) (=oleum oenotherae) und osmolyte aus extremophilen mikroorganismen | |
EP1635782A1 (de) | Gewebekulturmedien als bestandteil von kosmetika | |
KR100962052B1 (ko) | 락토바실러스 람노서스 유산균주 또는 이의 배양액을함유하는 여드름 개선용 화장료 조성물 | |
KR102391657B1 (ko) | 해조류 추출물을 포함하는 화장료 조성물 | |
EP1666099B1 (de) | Kosmetisches Hautmattierungsmittel | |
EP1100456A1 (de) | Verwendung von ectoin oder ectoin-derivaten in kosmetischen formulierungen | |
KR20160116733A (ko) | 카렌듈라 인퓨즈드 오일을 함유하는 비누 및 이의 제조방법 | |
WO2004031122A1 (de) | Neue curcumin/tetrahydrocurcumin-derivate für den einsatz in kosmetika, pharmazeutika und bei der ernährung | |
KR101749690B1 (ko) | 배초향을 함유하는 피지관리 및 모공개선 화장료 조성물 | |
KR101574556B1 (ko) | 둥근마, 신선초, 오크라 및 토란추출물을 유효성분으로 함유하는 피부보습용 화장료조성물 | |
KR101533624B1 (ko) | 항균 활성을 갖는 가락지나물 추출물을 포함하는 화장료 조성물 | |
KR101996732B1 (ko) | 용암해수를 이용하여 발효한 오메기주의 농축물을 포함하는 피부의 주름개선, 탄력개선 또는 보습용 화장료 조성물 | |
KR102367528B1 (ko) | 해조류 추출물을 유효성분으로 포함하는 화장료 조성물 | |
CN112245314A (zh) | 一种含四氢嘧啶的润唇膏及其制备方法 | |
KR100722673B1 (ko) | 방부제로서 글리세릴 카프릴레이트 및 고삼 추출물을함유하는 화장료 조성물 | |
KR100722674B1 (ko) | 방부제로서 글리세릴 카프릴레이트 및 맹죽엽 추출물을함유하는 화장료 조성물 | |
KR101688691B1 (ko) | 주름개선용 화장료 조성물 | |
KR20180069528A (ko) | 용안육 추출물을 포함하는 화장료 조성물 | |
KR102587124B1 (ko) | 보습성 및 롤링성이 향상된 마사지용 화장료 조성물 및 이를 포함하는 젤 | |
KR20210043098A (ko) | 영실 추출물 또는 이의 분리화합물을 함유하는 피부 미생물 조절용 화장료 조성물 | |
KR20050024159A (ko) | 흑미, 검정콩, 검정참깨, 익모초, 창포, 도엽 및 마치현의혼합 추출물을 함유하는 화장료 조성물 | |
KR20140110565A (ko) | 율피 추출물 또는 정제물을 유효성분으로 함유하는 피부노화의 예방 및 치료용 조성물 | |
KR101993324B1 (ko) | 피부 장벽 개선용 화장료 조성물 | |
DE10042710A1 (de) | Dermatologische oder kosmetische Zubereitung auf der Basis von Säugetierbutter | |
EP1311237A2 (de) | VERWENDUNG VON CYCLISCHEM 2,4 DIPHOSPHOGLYCERAT (cDGP) UND/ODER DERIVATEN IN KOSMETISCHEN UND DERMATOLOGISCHEN FORMULIERUNGEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005716456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007505492 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005716456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594576 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10594576 Country of ref document: US |